YASMIN Dosage & Rx Info | Uses, Side Effects

Yasmin Generic Name & Formulations

Legal Class

General Description

Drospirenone 3mg, ethinyl estradiol 30micrograms (21 tabs); inert (7 tabs).

Pharmacological Class

Progestin + estrogen.

How Supplied

Packs—3

Manufacturer

Bayer Corporation

Generic Availability

YES

Mechanism of Action

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Yasmin Indications

Indications

Oral contraception.

Yasmin Dosage and Administration

Adult

1 tab daily for 28 days; repeat.

Children

Pre-menarche: not applicable.

Yasmin Contraindications

Contraindications

Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or PE, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Concomitant ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

Yasmin Boxed Warnings

Boxed Warning

Cigarette smoking increases risk of serious cardiovascular events.

Yasmin Warnings/Precautions

Warnings/Precautions

Increased risk of cardiovascular events (eg, stroke, MI) esp. in cigarette smokers >35yrs of age. Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. History of depression; monitor and discontinue if serious depression recurs. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Monitor BP; discontinue if significant rise occurs. May need barrier contraception with Sunday starts or postpartum use (see full labeling). Pregnancy: discontinue if occurs. Nursing mothers: use other methods of contraception until breastfeeding is discontinued.

Yasmin Pharmacokinetics

Absorption

Absolute bioavailability: ~76% (drospirenone); ~40% (ethinyl estradiol).
Serum concentrations of drospirenone and ethinyl estradiol reached peak levels within 1–2 hours after administration.

Distribution

Apparent volume of distribution: 4 L/kg (drospirenone); 4–5 L/kg (ethinyl estradiol).
Drospirenone binds about 97% to other serum proteins. Ethinyl estradiol is bound to serum albumin approximately 98.5%.

Metabolism

Hepatic.

Elimination

Fecal, renal.
Half-life: ~30 hours (drospirenone); ~24 hours (ethinyl estradiol).

Yasmin Interactions

Interactions

See Contraindications. ALT elevations with HCV regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; discontinue Yasmin prior to starting HCV regimen and restart 2wks after completion. Monitor serum K⁺ during 1^st cycle with drugs that increase potassium (eg, ACE inhibitors, ARBs, NSAIDs, K⁺-sparing diuretics, K⁺-supplements, heparin, aldosterone antagonists); consider monitoring in high-risk patients taking concomitant long-term strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, indinavir, boceprevir, clarithromycin). May be antagonized by CYP3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate) (use backup contraception). May be affected by protease inhibitors, NNRTIs, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones.

Yasmin Adverse Reactions

Adverse Reactions

Premenstrual syndrome, headache/migraine, breast pain/tenderness/discomfort, nausea, vomiting, abdominal pain/tenderness/discomfort, mood changes; depression, pulmonary embolism, toxic skin eruption, uterine leiomyoma, serious thromboembolic events, liver disease.

Yasmin Clinical Trials

See Literature

Yasmin Note

Not Applicable

Yasmin Patient Counseling